The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Specific Activity: 0.036 pmol/min/μg
Assay Conditions: Add 50 μL reaction mix (100 μM S-adenosylmethionine, and 50-250 ng WHSC1/NSD2 in HMT buffer 7) to wells coated with the substrate. Incubate at 37oC for 2 hours. Add antibody against methylated K36 residue of histone H3, incubate 1 hour. Then, add secondary HRP-labeled antibody and incubate 30 minutes. Finally, add HRP chemiluminescent substrates and read luminescence.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
IL5 promoter REII region binding protein
MMSET type II
Multiple myeloma SET domain containing protein type III
Multiple myeloma SET domain protein
Multiple myeloma SET domain-containing protein
Nuclear receptor binding SET domain protein 2
Nuclear SET domain-containing protein 2
Probable histone-lysine N-methyltransferase NSD2
Trithorax/ash1 related protein 5
Wolf Hirschhorn syndrome candidate 1
Wolf Hirschhorn syndrome candidate 1 protein
Wolf-Hirschhorn syndrome candidate 1 protein
Probable histone methyltransferase (By similarity). May act as a transcription regulator that binds DNA and suppresses IL5 transcription.
Involvement in disease
Note=A chromosomal aberration involving WHSC1 is a cause of multiple myeloma tumors. Translocation t(4;14)(p16.3;q32.3) with IgH. Note=WHSC1 is located in the Wolf-Hirschhorn syndrome (WHS) critical region. WHS results from by sub-telomeric deletions in the short arm of chromosome 4. WHSC1 is deleted in every case, however deletion of linked genes contributes to both the severity of the core characteristics and the presence of the additional syndromic problems.